This lack of supply chain transparency is itself concerning
Based on data from the Phase 2 randomised controlled trial published in the New England Journal of Medicine in June 2023, nausea was reported as one of the most common adverse events among participants receiving retatrutide
Plus-size influencers have lamented publicly about how marketing agencies, telehealth companies and med spas will reach out to them seeking partnerships or wanting to pay them to promote the drugs
Per the KFF 2025 Employer Health Benefits Survey, 43% of firms with 5,000-plus employees cover GLP-1s for weight loss (up from 28%), 30% of firms with 1,000 to 4,999, and 16% of firms with 200 to 999
Victoria, speaking: And they were originally designed to help patients with Type 2 diabetes